Outlook Therapeutics

/Outlook Therapeutics

Overnight

Outlook Therapeutics

Biopharmaceutical

We are a late clinical-stage biopharmaceutical company working to develop the first ophthalmic formulation of bevacizumab approved by the U.S. Food and Drug Administration, or FDA, for use in retinal indications.

Symbol

OTLK

Last Closing Price
$1.22

Shares
10,000,000

Anticipated Date
January 29, 2021

Underwriters
H.C. WAINWRIGHT & CO., INC.

This offering is no longer available

To view the prospectus for Outlook Therapeutics, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange